Pregabalin and Transcutaneous Electrical Nerve Stimulation for Postherpetic Neuralgia Treatment
Pregabalin and Transcutaneous Electrical Nerve Stimulation for Postherpetic Neuralgia Treatment
复制标题
DOI：
10.1097/ajp.0b013e3181dda1ac
复制
发表时间：
2010-09-01
影响因子：
2.9
通讯作者：
Aurilio, Caterina
中科院分区：
文献类型：
--
作者：
Barbarisi, Manlio;Pace, Maria Caterina;Aurilio, Caterina
目的：带状疱疹后神经痛（PHN）是最常见的神经性疼痛之一，被描述为一种颤抖、撞击和收紧的灼痛，包括异常性疼痛和感觉异常。研究目的：评估普瑞巴林在经皮神经电刺激（TENS）期间使用的疗效PHN患者并分析身体活动和睡眠质量的任何变化。方法：本随机研究纳入了50至80岁的患者。我们招募了15名男性（平均年龄65 ± 8.6岁）和15名女性患者（平均年龄64 ± 8.2岁）。男性患者有持续15.6 +/- 8.8个月的神经性疼痛史，而女性患者有持续约14.9 +/- 8.6个月的神经性疼痛史。我们从1周的患者筛选开始，随后进行1周的普瑞巴林滴定。然后，我们为每位患者确定了普瑞巴林的剂量，以获得小于60 mm的视觉模拟量表（VAS）。合格的患者被随机分为2组，接受普瑞巴林+ TENS或普瑞巴林+TENS安慰剂治疗4周。患者进行了8次门诊访问，在此期间，他们完成了VAS，SF-麦吉尔疼痛问卷，和睡眠干扰questionnaire.Results：由此产生的数据表明，普瑞巴林管理与TENS减少疼痛PHN患者。治疗结束时，所有观察组的平均VAS均降低。用普瑞巴林300（P300）+TENS治疗的组具有30%的疼痛减轻，并且用普瑞巴林600（P600）+TENS治疗的组具有40%的疼痛减轻。P300+TENS组与P300+TENS安慰剂组之间的比较显示VAS的统计学显著降低（P300+TENS 25 +/- 0.67 vs. P300+TENS安慰剂39 +/- 1.19 P
Objective: Postherpetic neuralgia (PHN) is responsible for one of the most common types of neuropathic pain, described as a burning pain that shakes, hits, and tightens and includes allodynia and paresthesia.Aim of the Study: To evaluate the efficacy of Pregabalin when used during transcutaneous electric nerve stimulation (TENS) in patients with PHN and to analyze any changes in physical activity and sleep quality.Methods: Patients aged 50 to 80 years were included in this randomized study. We enrolled 15 male (average age 65 +/- 8.6 y) and 15 female patients (average age 64 +/- 8.2 y). The male patients had a history of neuropathic pain lasting 15.6 +/- 8.8 months whereas the female patients had a history of neuropathic pain lasting about 14.9 +/- 8.6 months. We began with 1 week of patient screening followed by a week of Pregabalin titration. Then, we established the dose of Pregabalin for each patient to obtain visual analog scale (VAS) of less than 60 mm. The eligible patients were randomly divided into 2 groups receiving Pregabalin + TENS or Pregabalin+TENS placebo for the following 4 weeks. Patients underwent 8 outpatient visits during which they completed VAS, SF-McGill Pain Questionnaire, and sleep interference questionnaire.Results: The resulting data showed that Pregabalin administration associated with TENS reduced pain in patients with PHN. At the end of the treatment, all the observed groups presented a reduction of mean VAS. The group treated with Pregabalin 300 (P300)+TENS had a reduction of pain of 30% and the group treated with Pregabalin 600 (P600)+TENS had a reduction of pain of 40%. The comparison between group P300+TENS versus group P300+TENS placebo showed a statistically significant reduction of VAS (P300+TENS 25 +/- 0.67 vs. P300+TENS placebo 39 +/- 1.19 P